アブストラクト
| Title | JAK阻害薬のJAK選択性と有用性 |
|---|---|
| Subtitle | 特集 関節リウマチの基礎・臨床 2021 Update |
| Authors | 森信暁雄 |
| Authors (kana) | |
| Organization | 京都大学大学院医学研究科内科学講座臨床免疫学 |
| Journal | Pharma Medica |
| Volume | 39 |
| Number | 2 |
| Page | 53-57 |
| Year/Month | 2021 / 2 |
| Article | 報告 |
| Publisher | メディカルレビュー社 |
| Abstract | 「はじめに」生物学的製剤の登場により関節リウマチ(rheumatoid arthritis:RA)の治療はこの20年間で劇的に変化した. 3系統の生物学的製剤に加え, わが国では, 2013年にはJAK(Janus kinase)阻害薬であるトファシチニブ(tofacitinib)が発売されたのを皮切りに, 現在5種類のJAK阻害薬が承認されている. JAK阻害薬は, 細胞内のリン酸化酵素であるJAKの働きを抑制する. JAKには4種類あるが, JAK阻害薬は各々のJAKを異なる選択性で抑制する. この選択性の違いがどのような意味をもつのかについて基礎的臨床的立場から考察する. 「I. JAK阻害薬の作用機序」サイトカインは, その構造や受容体の構造により分類される. |
| Practice | 薬学 |
| Keywords | JAK阻害薬, JAK選択性, サイトカイン, 関節リウマチ |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) Burmester GK, Bijlsma JWJ, Cutolo M, et al. Managing rheumatic and musculoskeletal diseases -past, present and future. Nat Rev Rheumatol. 2017: 13: 443-8.
- 2) Smolen JS, Aletaha D, McInnes IB, Rheumatoid arthritis. Lancet. 2016; 388: 2023-38.
- 3) O'Shea JJ, Laurence A. McInnes IB. Back to the Future: Oral Targeted Therapy for RA and Other Autoimmune Diseases. Nat Rev Rheumatol. 2013; 9: 173-82.
- 4) Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology(Oxford), 2018: 58: 953-62.
- 5) Morinobu A. JAK inhibitors for the treatment of rheumatoid arthritis, Immunol Med. 2020; 43: 148-55.
残りの11件を表示する
- 6) Clark JD. Flanagan ME, Telliez J-B. Discovery and Development of Janus Kinase(JAK) Inhibitors for Inflammatory Diseases. J Med Chem. 2014; 57: 5023-38.
- 7) Hamaguchi H. Discovery and structural characterization of peficitinib(ASP015K) as a novel and potent JAK inhibitor. Bioorg Med Chem, 2018; 26: 4971-83.
- 8) Dowty ME, Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019; 7: e00537.
- 9) Parmentier JM, Voss J, Graff C, et al. In Vitro and in Vivo Characterization of the JAK1 Selectivity of Upadacitinib (ABT-494). BMC Rheumatol. 2018; 2: 23.
- 10) McInnes IB, Byers NL, Higgs RE, et al. Comparison of Baricitinib, Upadacitinib, and Tofacitinib Mediated Regulation of Cytokine Signaling in Human Leukocyte Subpopulations. Arthritis Res Ther. 2019: 21: 183.
- 11) Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib(CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012; 64: 970-81.
- 12) Harrington R, AI Nokhatha SA, Conway R. JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data. J Inflamm Res. 2020: 13: 519-31.
- 13) Harnett J, Gerber R, Gruben D, et al. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. J Manag Care Spec Pharm. 2016: 22: 1457-71.
- 14) Bird P, Littlejohn G, Butcher B, et al. Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. Clin Rheumatol. 2020; 39: 2545-51.
- 15) Xie W, Huang Y, Xiao S, et a1. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlied trials. Ann Rheum Dis. 2019; 78: 1048-54.
- 16) Xeljanz Article-20 procedure. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots. First published: 06/03/2020 EMA/92517/2020
